Manara - Qatar Research Repository
3 files

Expert opinion on management of moderate-to-severe atopic dermatitis in Qatar

journal contribution
submitted on 2023-12-28, 06:30 and posted on 2023-12-28, 06:37 authored by Martin Steinhoff, Mehdi Adeli, Hassan Riad, Mohamed Allam, Ahmad Hazem, Ra’ed Alsmadi, Adel Mohamed Kamal, Waad Ibrahim, Maryam Ali Al-Nesf

Atopic dermatitis (AD), a chronic-relapsing inflammatory skin disorder, manifests with intense itching and eczematous lesions impairing quality of life. A heterogeneous population, and regional clinical practices for treating AD warrant the development of guidelines in Qatar. Therefore, guidelines for the management of moderate-to-severe AD in Qatar have been developed and discussed. Experts, including dermatologists and immunologists, used the Delphi technique for developing guidelines. Consensus was defined as ≥75% agreement or disagreement. AD is highly prevalent in primary and tertiary dermatology centers. AD-associated foot eczema and psoriasiform eczema are more frequent in Qatar than in Europe or USA. SCORing Atopic Dermatitis Index quantifies disease severity and itch. Dermatology Life Quality Index assesses the quality of life. Atopic Dermatitis Control Tool assesses long-term disease control. Moderate-severe AD benefits from new topicals like Janus-kinase-inhibitors or PDE4-inhibitors combined with phototherapy. Currently approved systemic agents are dupilumab, baricitinib, abrocitinib, and upadacitinib. New anti-IL-13 and anti-IL-31 therapies will soon be available. Patient education, allergy testing, and comorbidity consideration are critical in the management of AD. The expert panel established a comprehensive and pragmatic approach to managing moderate-to-severe AD, thereby assisting clinical decision-making for healthcare professionals in Qatar.

Other Information

Published in: Journal of Dermatological Treatment
See article on publisher's website:


Open Access funding provided by the Qatar National Library.



  • English


Taylor & Francis

Publication Year

  • 2023

License statement

This Item is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License.

Institution affiliated with

  • Hamad Medical Corporation
  • Al Wakra Hospital - HMC
  • Al Khor Hospital - HMC
  • Rumailah Hospital - HMC
  • Weill Cornell Medicine - Qatar
  • Sidra Medicine
  • Al Ahli Hospital
  • Al Emadi Hospital
  • Primary Health Care Corporation

Geographic coverage


Usage metrics

    Hamad Medical Corporation


    Ref. manager